Additionally, therapies such as adoptive T cell therapy, immune checkpoint inhibitors, angiogenesis and tyrosine kinase inhibitors, EZH1/2 and BET inhibitors (targeting sex-specific epigenetic and X chromosome inactivation) show sex dimorphism in anti-cancer treatment. The gene discussed is EZH1; the disease is cancer.